Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06456450
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-05-30
Brief Title:
Taiwan Severe Asthma Biologic Registry
Sponsor:
Taichung Veterans General Hospital
Organization:
Taichung Veterans General Hospital
Study Overview
Official Title:
Taiwan Severe Asthma Biologic Registry
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TARGET
Brief Summary:
This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan
The goal of this observational study is to discover the real-world effectiveness the impact of initiating switching of biologics and the possible prediction factors for selecting the best treatment option for patients
The main questions it aims to answer are
1 Determine risk factors associated with poor asthma control
2 Support the development of effectiveness and safety of therapeutic principles
3 To discover the real-world effectiveness of different biologics Clinical remission
4 To discover the impact of initiating biologics for severe asthma patients
5 To evaluate the prevalence of biologics switching and its benefits for patients
6 To compare the achievement rate of clinical remission among different biologics
Participants who are treated either with omalizumab mepolizumab benralizumab dupilzumab or Tezepelumab after January 1 2020 will be included in the study
The goal of this observational study is to discover the real-world effectiveness the impact of initiating switching of biologics and the possible prediction factors for selecting the best treatment option for patients
The main questions it aims to answer are
1 Determine risk factors associated with poor asthma control
2 Support the development of effectiveness and safety of therapeutic principles
3 To discover the real-world effectiveness of different biologics Clinical remission
4 To discover the impact of initiating biologics for severe asthma patients
5 To evaluate the prevalence of biologics switching and its benefits for patients
6 To compare the achievement rate of clinical remission among different biologics
Participants who are treated either with omalizumab mepolizumab benralizumab dupilzumab or Tezepelumab after January 1 2020 will be included in the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None